Glucagon-like peptide I improved glycemic control in type I diabetes

被引：56

作者：

Margaret T Behme

John Dupré

Thomas J McDonald

机构：

[1] Department of Medicine, University of Western Ontario, London Health Sciences Centre, London

来源：

BMC Endocrine Disorders | / 3卷 / 1期

关键词：

Glycemic Control; Gastric Emptying; Intensive Insulin Therapy; Pancreatic Polypeptide; Continuous Subcutaneous Insulin Infusion;

D O I：

10.1186/1472-6823-3-3

中图分类号：

学科分类号：

摘要：

Background: Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying. We examined the potential of GLP-1 to improve glycemic control in type 1 diabetes with no endogenous insulin secretion. Methods: Dose-finding studies were carried out to establish mid range doses for delay of gastric emptying indicated by postponement of pancreatic polypeptide responses after meals. The selected dose of 0.63 micrograms/kg GLP-1 was administered before breakfast and lunch in 8-hour studies in hospital to establish the efficacy and safety of GLP-1. In outside-hospital studies, GLP-1 or vehicle was self-administered double-blind before meals with usual insulin for five consecutive days by five males and three females with well-controlled C-peptide-negative type 1 diabetes. Capillary blood glucose values were self-monitored before meals, at 30 and 60 min after breakfast and supper, and at bedtime. Breakfast tests with GLP-1 were conducted on the day before and on the day after 5-day studies. Paired t-tests and ANOVA were used for statistical analysis. Results: In 8-hour studies time-averaged incremental (delta) areas under the curves(AUC) for plasma glucose through 8 hours were decreased by GLP-1 compared to vehicle (3.2 ± 0.9, mean ± se, vs 5.4 ± 0.8 mmol/l, p < .05), and for pancreatic polypeptide, an indicator of gastric emptying, through 30 min after meals (4.0 ± 3.1 vs 37 ± 9.6 pmol/l, p < .05) with no adverse effects. Incremental glucagon levels through 60 min after meals were depressed by GLP-1 compared to vehicle (-3.7 ± 2.5 vs 3.1 ± 1.9 ng/l, p < .04). In 5-day studies, AUC for capillary blood glucose levels were lower with GLP-1 than with vehicle (-0.64 ± 0.33 vs 0.34 ± 0.26 mmol/l, p < .05). No assisted episode of hypoglycaemia or change in insulin dosage occurred. Breakfast tests on the days immediately before and after 5-day trials showed no change in the effects of GLP-1. Conclusion: We have demonstrated that subcutaneous GLP-1 can improve glucose control in type 1 diabetes without adverse effects when self-administered before meals with usual insulin during established intensive insulin treatment programs. © 2003 Behme et al; licensee BioMed Central Ltd.

引用

共 13 条

[1] Holst J.J., Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1, Diabetes Metab. Res. Rev., 18, pp. 430-441, (2002)
[2] Todd J.F., Wilding J.P.H., Edwards C.M.B., Khan F.A., Ghatei M.A., Bloom S.R., Glucagon-like peptide-1 (GLP-1) - A trial of treatment in noninsulin-dependent diabetes mellitus, European J. Clin. Invest., 27, pp. 533-536, (1997)
[3] Zander M., Madsbad S., Lysgaard J., Holst J.J., Effect of 6-week course of glucagon-like peptide 1 on glucose control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study, Lancet, 359, pp. 824-830, (2002)
[4] Gutniak M., Orskov C., Holst J.J., Ahren B., Efendic S., Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus, N. Engl. J. Med., 326, pp. 1316-1322, (1992)
[5] Dupre J., Behme M.T., Hramiak I.M., McFarlane P., Williamson M.P., Zabel P., McDonald T.J., Glucagon-like peptide 1 reduces post-prandial glucose excursions in IDDM, Diabetes, 44, pp. 626-630, (1995)
[6] Creutzfeldt W.O., Kleine N., Willms B., Orskov C., Holst J.J., Nauck M.A., Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients, Diabetes Care, 19, pp. 580-586, (1996)
[7] Dupre J., Behme M.T., Hramiak I.M., McDonald T.J., Subcutaneous glucagon-like peptide-1 combined with insulin normalizes postprandial glycemia in IDDM, Diabetes Care, 20, pp. 381-384, (1997)
[8] Dupre J., Jenner M., Mahon J.L., Purdon C., Rodger N.W., Stiller C.R., Endocrine-metabolic function in remission-phase insulin-dependent diabetes mellitus (IDDM) during administration of cyclosporin, Diabetes, 40, pp. 598-604, (1991)
[9] Vella A., Shah P., Basu R., Basu A., Camilleri M., Schwenk F.W., Holst J.J., Rizza R.A., Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes, Diabetes, 50, pp. 565-572, (2001)
[10] Kraegen E.W., Chisholm D.J., McNamara M.E., Timing of insulin delivery with meals, Horm. Metab. Res., 13, pp. 365-367, (1981)

← 1 2 →